国邦医药
(605507)
| 流通市值：61.31亿 | | | 总市值：113.55亿 |
| 流通股本：3.02亿 | | | 总股本：5.59亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,440,055,937.13 | 5,890,839,205.64 | 4,418,147,150.19 | 2,892,356,514.66 |
| 营业收入 | 1,440,055,937.13 | 5,890,839,205.64 | 4,418,147,150.19 | 2,892,356,514.66 |
| 二、营业总成本 | 1,209,046,358.94 | 5,007,120,720.06 | 3,724,615,529.84 | 2,397,206,396.4 |
| 营业成本 | 1,059,329,845.05 | 4,418,112,641.94 | 3,262,008,778.71 | 2,123,115,433.25 |
| 税金及附加 | 13,378,744.69 | 46,642,502.55 | 32,093,286.11 | 19,373,932.9 |
| 销售费用 | 17,759,167.77 | 79,464,262.57 | 50,467,194.59 | 32,245,331.34 |
| 管理费用 | 84,760,575.69 | 277,666,341.73 | 228,092,919.66 | 150,610,298.4 |
| 研发费用 | 38,737,666.55 | 215,051,819.93 | 160,287,477.94 | 92,959,963.79 |
| 财务费用 | -4,919,640.81 | -29,816,848.66 | -8,334,127.17 | -21,098,563.28 |
| 其中:利息费用 | 5,616,421.64 | 27,279,186.8 | 21,636,062.26 | 14,774,714.01 |
| 其中:利息收入 | 6,953,524.35 | 29,937,287.56 | 24,661,485.05 | 19,396,872.95 |
| 加:公允价值变动收益 | 4,230,002.74 | 14,402,252.11 | 10,138,187.08 | 5,811,583.22 |
| 加:投资收益 | 2,807,775.6 | 12,948,302.52 | 11,451,609.08 | 10,280,070.46 |
| 资产处置收益 | - | -9,107,023.5 | 2,260.9 | 2,260.9 |
| 资产减值损失(新) | 4,152,013.69 | -25,825,347.98 | -54,049,293.84 | -44,541,385.02 |
| 信用减值损失(新) | -7,150,574.85 | -12,248,273.62 | -13,516,973.52 | -13,879,239.41 |
| 其他收益 | 13,429,361.22 | 31,179,052.69 | 26,390,255.48 | 19,635,860.89 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 248,478,156.59 | 895,067,447.8 | 673,947,665.53 | 472,459,269.3 |
| 加:营业外收入 | 2,274,944.35 | 3,740,557.65 | 3,435,952.8 | 2,604,372.17 |
| 减:营业外支出 | 1,924,503.49 | 10,838,221.35 | 12,751,207 | 10,974,493.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 248,828,597.45 | 887,969,784.1 | 664,632,411.33 | 464,089,147.75 |
| 减:所得税费用 | 34,568,922.44 | 107,392,285.07 | 85,994,213.27 | 59,720,156.13 |
| 六、净利润 | 214,259,675.01 | 780,577,499.03 | 578,638,198.06 | 404,368,991.62 |
| 持续经营净利润 | 214,259,675.01 | 780,577,499.03 | 578,638,198.06 | 404,368,991.62 |
| 归属于母公司股东的净利润 | 214,977,071.32 | 781,595,425.54 | 578,884,934.79 | 404,597,903.42 |
| 少数股东损益 | -717,396.31 | -1,017,926.51 | -246,736.73 | -228,911.8 |
| (一)基本每股收益 | 0.38 | 1.4 | 1.04 | 0.73 |
| (二)稀释每股收益 | 0.38 | 1.4 | 1.04 | 0.73 |
| 九、综合收益总额 | 214,259,675.01 | 780,577,499.03 | 578,638,198.06 | 404,368,991.62 |
| 归属于母公司股东的综合收益总额 | 214,977,071.32 | 781,595,425.54 | 578,884,934.79 | 404,597,903.42 |
| 归属于少数股东的综合收益总额 | -717,396.31 | -1,017,926.51 | -246,736.73 | -228,911.8 |
| 公告日期 | 2025-04-16 | 2025-03-28 | 2024-10-19 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |